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ORIGINAL ARTICLE
Frequency of worsening liver function in severe dengue hepatitis patients
receiving paracetamol: A retrospective analysis of hospital data
Ahsan Ali Syed, Faisal Aslam, Haris Hakeem, Faraz Siddiqui, Noreen Nasir

Abstract
Objective: To determine the frequency of worsening liver function among hospital in-patients with severe dengue
hepatitis receiving paracetamol.
Methods: This retrospective study was conducted at the Department of Medicine, Aga Khan University Hospital,
Karachi, and comprised records of dengue patients with severe hepatitis who received paracetamol for control of
fever between June 2007 and December 2014. Alanine aminotransferase at baseline and following paracetamol
administration was noted, as well as dosage and duration of paracetamol, along with participants' demographic
details. Frequency of patients who developed worsening or improvement of alanine aminotransferase was also
noted. SPSS 19 was used for data analysis.
Results: Of the 113 subjects, 73(64.6%) were male and 40(35.4%) were female. Overall improvement was observed
in subsequent alanine aminotransferase levels (491 units per litre, IQR 356.5 TO 775 vs 151 units per litre, IQR 49.5 to
299.5). Most commonly prescribed dose of paracetamol was 2g (IQR 1 to 5 grams), which was taken for a median
duration of 1 day (IQR 1 to 3 days). Moreover, 100(88.5 %) patients showed improvement in alanine
aminotransferase. Only 13(11.5 %) patients developed worsening of alanine aminotransferase. Of those with
worsening liver function, 8(61.5 %) were discharged home with no clinical deterioration and 5(38.5 %) deaths were
observed. However, causes of deaths were unrelated to liver dysfunction.
Conclusion: The frequency of worsening liver function following paracetamol administration in patients with
severe dengue hepatitis was relatively low.
Keywords: Dengue, Hepatitis, Paracetamol, Liver dysfunction. (JPMA 67: 400; 2017)

Introduction
Dengue (DEN) is a growing clinical and public health
problem in the developing world. The World Health
Organisation (WHO) estimates at least 50 million
occurrences of dengue every year all over the world. As
many as 100 countries have been labelled as being
endemic to the problem, with South Asia being declared
as a high-risk endemic population by the WHO. Pakistan
itself reported its first dengue outbreak in 1994, following
which the disease has frequently resurfaced in a number
of outbreaks over the years.1
Although dengue presents as a self-limiting febrile illness,
it can also lead to more severe, life-threatening forms like
dengue haemorrhagic fever (DHF) and dengue shock
syndrome (DSS). Gastrointestinal manifestations like
hepatitis, acute liver failure, cholecystitis, pancreatitis and
diarrhoea have been reported in literature.2 Acute
hepatitis can occur in 30-90% of patients with dengue.
However, the rise in transaminase level remains in mild to
moderate range and only 3-11% of patients may develop
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severe hepatitis.2 A previous study3 done in Pakistan,
demonstrated that 15% of dengue patients developed
severe hepatitis (alanine aminotransferase [ALT] >300
units per litre [U/L]), and was associated with longer
hospital stay, increased mortality and other
complications. Thus, severe hepatitis is a bad prognostic
indicator in patients with dengue fever. Despite being a
self-limiting illness at the outset, some dengue patients
are at risk of fulminant hepatic failure (FHF), although this
is rare.3
The exact mechanism of liver involvement in dengue is
not fully understood, but is believed to be the effect of
viral replication within hepatocytes or a result of
dysregulated immune response. Some viral strains, like
DEN-1 and DEN-3, also have a prominent liver tropism.2,4
In addition to ischaemic or hypoxic liver injury due to
circulatory compromise, self-administered paracetamol
for relief of fever and body ache in the initial phase of
illness may also aggravate the underlying mechanisms of
liver injury in dengue. The evidence on the role of
paracetamol in precipitating liver injury is, however,
inconclusive at this point.2,3,5,6 The WHO recommends
paracetamol as an antipyretic of choice rather than nonsteroidal anti-inflammatory drugs (NSAIDs) due to an
J Pak Med Assoc
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inherent bleeding risk with the latter due to low platelet
counts in dengue infection. However, current guidelines
do not mention which drug to use as an antipyretic in
patients suffering from severe dengue hepatitis.7 In
clinical practice, physicians do not prescribe paracetamol
to patients with acute hepatitis due to risk of developing
FHF.8 Yet, prudent management in such patients is to give
half the maximum dose of paracetamol, i.e. 2g rather than
4g per day. This figure is arbitrary and without any
supportive evidence from medical literature.8 In
accordance with WHO guidelines, physicians prescribe
paracetamol for fever in dengue even in the presence of
deranged liver function tests (LFTs).7
At present, scientific evidence is lacking on the
management of fever in patients with dengue fever (DF)
who also have severe hepatitis. To the best of our
knowledge, no study has been done previously to
determine the frequency of liver toxicity of paracetamol in
patients with severe dengue hepatitis. The current study
was planned to determine the frequency of worsening
liver function based on information available from a
tertiary care hospital.

Patients and Methods
This retrospective study was conducted at the
Department of Medicine, Aga Khan University Hospital
(AKUH), Karachi, and comprised medical records of all
patients aged more than 16 years who were admitted
with a diagnosis of dengue infection with severe hepatitis
and received paracetamol during hospital stay from June
2007 to December 2014. The AKUH is a 700-bed tertiary
care centre which receives patients from all over Pakistan.
Ethical approval for the study was obtained from the
institutional ethics review committee.
All patients having underlying chronic liver disease or
acute hepatitis due to any cause other than dengue
infection were excluded. A case of dengue fever was
defined as a patient who was admitted with fever and had
a positive dengue immunoglobulin M (IgM) antibody or
dengue antigen. Severe dengue hepatitis was defined as
serum ALT level more than 300 U/L.3 Worsening of liver
function was described as an increase in ALT levels of
patients on subsequent investigations. Conversely,
improved liver function was described as decreased ALT
levels on subsequent investigations.
We collected data regarding dosage, cumulative dose,
route of administration, frequency and duration (in days)
of paracetamol. ALT level at the time of paracetamol
administration and subsequent latest ALT level after
receiving paracetamol were recorded. The subsequent
ALT levels were recorded whether done during hospital
Vol. 67, No. 3, March 2017

stay, which were done in early morning daily regardless of
last paracetamol dose timing, or in a clinic follow-up after
discharge from hospital, and the duration between
baseline and subsequent ALT investigations was noted.
We compared average values of ALT on baseline and
subsequent investigations for the overall sample.
Frequency of patients with worsening liver function was
calculated for the study subjects. Participants' details
regarding age, gender, frequency and cause of deaths
were also collected. All collected data was verified by the
primary investigator to enhance the accuracy. We used
the Wilcoxon rank-sum test to compare differences in ALT
values between the improving and worsening liver
function groups, both at baseline and at subsequent
investigations. P<0.05 was considered significant. SPSS 19
was used for data analysis.

Results
Of the 2,432 patients, 113(4.65%) qualified to be included.
Of them, 73(64.6%) were male and 40(35.4%) were female.
The mean age of the participants was 33 ± 13.13 years.
The median dose of paracetamol received was 2gm (IQR 1
to 5 grams), which was taken for a median duration of 1
day (IQR 1 to 3 days). The most common route of
Table-1: Baseline characteristics of patients with severe dengue hepatitis receiving
paracetamol (n=113).
n (%)
Age (years)
16-40
41-60
61 and above
Gender
Male
Female
Baseline ALT
Route of paracetamol administration
Intravenous
Oral
Rectal
Combination
Cumulative dose of paracetamol received
1-3 gm
4-5 gm
6gm or above
Median
Duration of paracetamol use
1-3 days
4-5 days
6 or above
Median
ALT: Alanine aminotransferase
IQR: Interquartile range
U/L: Units per litre.

89 (78.8)
18 (15.9)
6 (5.3)
73 (64.6)
40 (35.4)
491(IQR 356.5 to 775) U/L
51 (45.1)
45 (39.8)
2 (1.8)
15 (13.3)
74 (65.5)
13 (11.5)
26 (23)
2 (IQR 1 to 5) grams
92 (81.4)
13 (11.5)
8 (7.1)
1 (IQR 1 to 3) days
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administration was intravenous 51(45.1 %), followed by
oral 45(39.8 %) and rectal 2(1.8 %) routes. In addition,
15(13.3%) patients received the drug in a varying
combination of these routes (Table 1).
An overall improvement in liver function was observed

between the two groups prior to paracetamol
administration, and found that the ALT values were similar
(p=0.15). However, the difference observed on
subsequent ALT measurements was statistically
significant (p<0.001) (Figure-2). This difference was
unrelated to the amount of paracetamol received by the
groups, which was comparable.
Of the patients with worsening liver function, 8 (61.5%)
were discharged safely with no further clinical worsening.
Documented proof of improving ALT was not found in
medical records of these patients. Although mortality
among all the patients with worsening liver function was
proportionately higher than in patients with improving
ALT, our search of the medical records did not reveal any
evidence of hepatic failure, or worsened liver function to
be implicated. The causes of death were identified as
either DSS, respiratory or renal failure in all 5(38.5%) cases.
It was also observed that a higher frequency of male
patients and those in the 16-40 years age bracket
demonstrated worsened ALT (Table-2).

ALT: Alanine aminotransferase.

U/L: Units per litre

Figure-1: Median ALT levels of study participants before and after paracetamol
administration (n=113).

following paracetamol administration, based on
subsequent ALT investigations which were performed on
an average of 7 days after baseline (Figure 1). Thus,

ALT: Alanine aminotransferase.

U/L: Units per litre

Figure-2: Baseline and subsequent ALT levels stratified by status of liver function
after paracetamol administration.

100(88.5%) patients showed subsequent improvement in
ALT whereas ALT levels worsened in 13(11.5 %) patients.
Out of these 13 patients, 12(92.3%) were males and
1(7.7%) was female. We compared baseline ALT values

Median initial ALT and median raised subsequent ALT
were 398 U/L (IQR 201.5 to 668.5 U/L) and 2,107 U/L (IQR
1,496 to 2,799 U/L), respectively, among the patients who
expired.

Discussion
Through a comprehensive review of our records, we
were able to observe the clinical progress of 113 patients
with severe dengue hepatitis who had received
paracetamol. It was observed that a considerable
proportion of the subjects showed improvement of
subsequent ALT after receiving paracetamol, with only
13(11.5%) patients showing worsening of ALT. There
were no significant differences between the doses of
paracetamol received by both groups. Among the 13
patients who showed worsening of subsequent ALT,
major proportion of patients did not show any clinical
deterioration and were discharged home safely. We
observed five mortalities in this group, however, none of
the patients died due to liver dysfunction. Similarly, not
a single patient went into hepatic failure. Secondly, all of
these patients were critically ill at the time of death and
had developed severe complications of dengue fever
which could explain these raised ALT levels very well.
These results show that frequency of worsening liver
function in patients with severe dengue hepatitis upon
receiving paracetamol was relatively low, and may not
be directly related to mortality. However, we do not
underestimate the importance of frequent liver function
monitoring in such patients. A higher proportion of
males in our study showed subsequent ALT worsening,
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Table-2: Frequency and comparison of subsequent ALT levels in patients with severe
dengue hepatitis stratified by age, gender and mortality status (n=113).

Age
15-40 years
41-60 years
61 years and above
Gender
Male
Female
Mortality
Expired
Alive

N

ALT improved

ALT worsened

89 (%)
18 (%)
6 (%)

78 (%)
16 (%)
6 (%)

11 (%)
2 (%)
0 (%)

73(%)
40 (%)

61 (%)
39 (%)

12 (%)
1 (%)

12 (%)
101 (%)

7 (%)
93 (%)

5 (%)
8 (%)

ALT: Alanine aminotransferase.

small sample size available for analysis. Since physicians
usually do not follow ALT after clinical improvement we
could not study the long-term effects of paracetamol. We
were also unable to document whether any patients selfmanaged on paracetamol, or study the variation in ALT
levels by the dose of paracetamol taken, which is one of
our major limitations. However, we tried to highlight the
complexity in decision-making by physicians in managing
severe dengue hepatitis, and recommend WHO
guidelines for dengue fever to be updated regarding the
safe dosing and duration of paracetamol in these
patients.10 In brief, our study did not show any significant
harm in severe dengue hepatitis patients who received
paracetamol.

Conclusion
which might suggest that males are prone to develop
worsening of ALT in this study population. However, this
should be interpreted with caution due to
overrepresentation of male subjects in our sample.
Moreover, a higher proportion of mortality was
observed in patients with worsening ALT. This is
consistent with the findings of Almas et al.9 and Parkash
et al.3 which suggest worsening ALT in dengue to be
associated with high mortality. This could possibly be
due to a number of disease- or patient-related factors
other than paracetamol and may include direct attack of
virus itself on liver cells, or unregulated host immune
response against the virus.3
We know that severe dengue hepatitis is associated with
increased mortality in patients with dengue infection.3,9
Secondly, paracetamol is known to affect liver function
in patients with dengue hepatitis;3,4,10,11 it may also lead
to acute liver failure in acute viral hepatitis.8 These three
reasons render physicians to use paracetamol with great
caution in dengue patients with severe hepatitis. NSAIDs
have already been contraindicated in WHO guidelines.7
However, these guidelines do not mention clearly
whether paracetamol can be given in the presence of
severe hepatitis in dengue infection.7,10 This means there
is no safe drug available to physicians to deal with the
fever of patients with dengue infection, particularly with
deranged liver function. In these circumstances our
study demonstrated paracetamol as a fairly safe
antipyretic for treating dengue patients, even in severe
hepatitis. To our knowledge, no study has ever
addressed this issue before.
The current study was not without its limitations. Despite
its clinical relevance, the interpretation of our study
results may need caution as it presents only descriptive
findings based on retrospective data, with a relatively
Vol. 67, No. 3, March 2017

The observed frequency of worsened liver function in
severe dengue hepatitis following paracetamol
administration was low. In the absence of clinical
guidelines, physicians may continue to prescribe
paracetamol for the relief of fever in these patients.
However, larger observational or experimental studies
with a control arm are strongly recommended to establish
the clinical safety of paracetamol administration in severe
dengue hepatitis.
Disclaimer: None.
Conflict of Interest: None.
Source of Funding: None.

References
1.
2.

3.

4.

5.

6.

7.

8.

9.

Jahan F. Dengue Fever (DF) in Pakistan. Asia Pac Fam Med. 2011;
10:1.
Tan SS, Bujang MA. The clinical features and outcomes of acute
liver failure associated with dengue infection in adults: a case
series. Braz J Infect Dis. 2013; 17:164-9.
Parkash O, Almas A, Jafri SM, Hamid S, Akhtar J, Alishah H. Severity
of acute hepatitis and its outcome in patients with dengue fever
in a tertiary care hospital Karachi, Pakistan (South Asia). BMC
Gastroenterol. 2010;10:43.
Mourao MP, Lacerda MV, Bastos Mde S, Albuquerque BC, Alecrim
WD. Dengue hemorrhagic fever and acute hepatitis: a case report.
Braz J Infect Dis. 2004; 8:461-4.
Souza LJ, Alves JG, Nogueira RM, Gicovate Neto C, Bastos DA,
Siqueira EW, et al. Aminotransferase changes and acute hepatitis
in patients with dengue fever: analysis of 1,585 cases. Braz J Infect
Dis. 2004; 8:156-63.
Viswanathan S, Iqbal N, Anemon PP, Kumar GS. Fatal fulminant
hepatic failure in a diabetic with primary dengue. J Trop Med.
2010; 2010:413561.
WHO. Dengue guidelines for diagnosis, treatment, prevention and
control. [Online] 2009 [cited 2013 June 14]. Available from: URL:
http://www.who.int/rpc/guidelines/9789241547871/en/.
Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study
Group: lowering the risks of hepatic failure. Hepatology. 2004;
40:6-9.
Almas A, Parkash O, Akhter J. Clinical factors associated with

404
10.

11.

A. A. Syed, F. Aslam, H. Hakeem, et al
mortality in dengue infection at a tertiary care center. Southeast
Asian J Trop Med Public Health. 2010; 41:333-40.
Gan CS, Chong SY, Lum LC, Lee WS. Regular paracetamol in
severe dengue: a lethal combination? Singapore Med J. 2013;
54:e35-7.
Seneviratne SL, Malavige GN, de Silva HJ. Pathogenesis of liver
involvement during dengue viral infections. Trans R Soc Trop Med
Hyg. 2006; 100:608-14.

J Pak Med Assoc

